- Trial phase
- Approved
- Time to market
- Already approved and marketed (Orencia since 2005). Any Dr. Reddy's biosimilar status is unclear from available data.
- Why 4/10
- Abatacept/Orencia is an already-approved, marketed drug with no pending PDUFA or pivotal readout in the next ~12 months. For BMY, it is one of many products in a large portfolio. For RDY, any abatacept biosimilar is a minor pipeline asset. No hard binary catalyst is scheduled, so the impact score defaults to 4.
For BMY investors, Orencia (abatacept) is a mature, slow-growth biologic facing eventual biosimilar competition; it is not a near-term binary catalyst. For RDY, any abatacept biosimilar is a small part of a large generics portfolio, watch for FDA approval/launch announcements but don't expect a major share-price move from this product alone.
Price Chart
Executive Summary
Abatacept (brand name Orencia) is an FDA-approved biologic drug developed by Bristol-Myers Squibb (BMY) for autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. First approved in 2005, it is a mature, marketed product with steady but slow-growing sales. Dr. Reddy's Laboratories (RDY) lists abatacept in its drug portfolio per recent SEC filings, suggesting a biosimilar version is in development or commercialization. For BMY, Orencia is one of many products in a large diversified portfolio. For RDY, any abatacept biosimilar would be a minor part of a broad generics/biosimilars business. No near-term binary catalysts are scheduled for this drug.
How It Works
Abatacept is a biologic drug (a fusion protein) that calms an overactive immune system. It works by blocking a key 'on' switch that immune cells need to become activated, specifically, it binds to proteins (CD80/CD86) on immune cells and prevents them from fully activating T-cells, which are the immune cells that drive inflammation in autoimmune diseases like rheumatoid arthritis.
Trial Status
Abatacept/Orencia is FDA-approved and commercially marketed by Bristol-Myers Squibb. Multiple investigator-sponsored Phase 2/3 trials in additional indications (kidney transplantation, myocarditis, polymyalgia rheumatica, graft-versus-host disease) have been completed. Dr. Reddy's Laboratories references abatacept in its drug portfolio per its Q2 FY2027 earnings filing, suggesting a biosimilar version is in their pipeline.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalysts identified for abatacept/Orencia. For BMY, watch quarterly Orencia sales trends. For RDY, watch for any FDA filing or approval announcement of an abatacept biosimilar.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
DR REDDYS LABORATORIES LTD 6-K RDY ·Originating report